Related Experiment Video

Updated: Nov 12, 2025

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells
10:27

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Published on: March 9, 2012

11.0K

α-Arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis

Aleena K S Arakaki1,2,3, Wen-An Pan1, Helen Wedegaertner1,2

  • 1Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

Journal of Cell Science
|March 16, 2021
PubMed

Insights

Alpha-arrestin domain containing protein 3 (ARRDC3) suppresses triple-negative breast cancer (TNBC) metastasis by sequestering TAZ, a key effector of G-protein-coupled receptor signaling. This interaction inhibits tumor cell migration and invasion, highlighting ARRDC3 as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Triple-negative breast carcinoma (TNBC) is a highly metastatic breast cancer subtype lacking targeted therapies.
  • Alpha-arrestin domain containing protein 3 (ARRDC3) acts as a tumor suppressor in TNBC.
  • Dysregulation of G-protein-coupled receptor (GPCR) signaling and the Hippo pathway is linked to breast cancer progression.

Purpose of the Study:

  • To elucidate the mechanisms by which ARRDC3 suppresses TNBC metastasis.
  • To investigate the role of ARRDC3 in regulating GPCR-induced Hippo signaling.
  • To identify the key molecular interactions underlying ARRDC3's tumor suppressor function.

Main Methods:

  • Investigated the interaction between ARRDC3 and TAZ (WWTR1), a transcriptional co-activator of the Hippo pathway.
  • Assessed the role of ARRDC3 in regulating protease-activated receptor 1 (PAR1) signaling.
  • Utilized in vivo models to evaluate the impact of ARRDC3 on TNBC cell migration, invasion, and lung metastasis.

Main Results:

  • TAZ is identified as a major effector of GPCR signaling required for TNBC migration and invasion.
  • ARRDC3 suppresses PAR1-induced Hippo signaling by sequestering TAZ, independent of PAR1 trafficking.
  • The interaction between ARRDC3's PPXY motifs and TAZ's WW domain is critical for suppressing TNBC metastasis in vivo.

Conclusions:

  • ARRDC3 plays a multifaceted role in suppressing TNBC by regulating GPCR-induced TAZ activity.
  • Targeting the ARRDC3-TAZ interaction presents a potential therapeutic strategy for TNBC.
  • This study reveals novel mechanisms of tumor suppression by ARRDC3 in metastatic breast cancer.
Keywords:
Hippo pathwayLPAPAR1PAR2S1PThrombin

More Related Videos

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

11.2K
RhoC GTPase Activation Assay09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

12.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.7K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.1K